📊 KMTS Key Takeaways
Is KMTS a Good Investment? Thesis Analysis
Kestra Medical is a pre-profitable medical device company with exceptional revenue growth (115% YoY) and a fortress balance sheet ($291M cash, 7.32x current ratio), but faces severe operational challenges with -$88.2M negative free cash flow and an operating margin of -143.5%, indicating unsustainable unit economics without significant operational leverage improvements.
Why Buy KMTS? Key Strengths
- Exceptional top-line growth of 115% YoY demonstrating strong market demand
- Fortress balance sheet with $291.3M in cash and minimal debt (0.15x D/E ratio) providing 3+ years of runway
- Healthy gross margin of 49.9% indicating viable core product economics
- Net losses improving 9.8% YoY suggesting operational trajectory toward profitability
- Excellent liquidity with 7.32x current ratio providing financial flexibility
KMTS Investment Risks to Consider
- Severe unprofitability with -$139.5% net margin and -$143.5% operating margin indicating massive SG&A/R&D spend relative to revenue
- Negative operating cash flow of -$63.0M and negative free cash flow of -$88.2M showing company burns $1.33 for every $1.00 in revenue
- No visible path to profitability in current trajectory requiring dramatic margin expansion or revenue acceleration to achieve breakeven
- Medical device sector execution risk with long development and commercialization cycles vulnerable to regulatory, clinical, or market adoption delays
- Cash burn rate of $88.2M annually will require either additional capital raises or rapid profitability improvements within 3+ years
Key Metrics to Watch
- Operating cash flow trajectory and path to positive OCF relative to revenue growth
- Gross margin sustainability and expansion potential as manufacturing scales
- Operating expense ratio relative to revenue - need to see SG&A and R&D leverage
- Quarterly revenue growth sustainability - whether 115% growth rate can be maintained
- Free cash flow breakeven timeline and cash runway depletion estimates
KMTS Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 7.32x current ratio provides a solid financial cushion.
KMTS Profitability Ratios
KMTS vs Healthcare Sector
How KESTRA MEDICAL TECHNOLOGIES, LTD. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is KMTS Overvalued or Undervalued?
Based on fundamental analysis, KESTRA MEDICAL TECHNOLOGIES, LTD. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
KMTS Balance Sheet & Liquidity
KMTS 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: KESTRA MEDICAL TECHNOLOGIES, LTD.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-5.07 indicates the company is currently unprofitable.
KMTS Growth Metrics (YoY)
KMTS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $15.1M | -$21.5M | $-0.61 |
| Q2 2025 | $14.7M | -$20.4M | $-0.64 |
| Q1 2025 | $12.8M | -$19.9M | $-0.50 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
KMTS Capital Allocation
KMTS SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for KESTRA MEDICAL TECHNOLOGIES, LTD. (CIK: 0001877184)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KMTS
What is the AI rating for KMTS?
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) has an AI rating of HOLD with 55% confidence, based on fundamental analysis of SEC EDGAR filings.
What are KMTS's key strengths?
Claude: Exceptional top-line growth of 115% YoY demonstrating strong market demand. Fortress balance sheet with $291.3M in cash and minimal debt (0.15x D/E ratio) providing 3+ years of runway.
What are the risks of investing in KMTS?
Claude: Severe unprofitability with -$139.5% net margin and -$143.5% operating margin indicating massive SG&A/R&D spend relative to revenue. Negative operating cash flow of -$63.0M and negative free cash flow of -$88.2M showing company burns $1.33 for every $1.00 in revenue.
What is KMTS's revenue and growth?
KESTRA MEDICAL TECHNOLOGIES, LTD. reported revenue of $66.5M.
Does KMTS pay dividends?
KESTRA MEDICAL TECHNOLOGIES, LTD. does not currently pay dividends.
Where can I find KMTS SEC filings?
Official SEC filings for KESTRA MEDICAL TECHNOLOGIES, LTD. (CIK: 0001877184) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KMTS's EPS?
KESTRA MEDICAL TECHNOLOGIES, LTD. has a diluted EPS of $-1.76.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KMTS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, KESTRA MEDICAL TECHNOLOGIES, LTD. has a HOLD rating with 55% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KMTS stock overvalued or undervalued?
Valuation metrics for KMTS: ROE of -32.2% (sector avg: 15%), net margin of -139.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KMTS stock in 2026?
Our dual AI analysis gives KESTRA MEDICAL TECHNOLOGIES, LTD. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KMTS's free cash flow?
KESTRA MEDICAL TECHNOLOGIES, LTD.'s operating cash flow is $-63.0M, with capital expenditures of $25.2M. FCF margin is -132.7%.
How does KMTS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -139.5% (avg: 12%), ROE -32.2% (avg: 15%), current ratio 7.32 (avg: 2).